NCT01916057 (CANHPARI) is a NA clinical trial of 18F-FDG PET Scan in Invasive Fungal Disease, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT01916057?

NCT01916057 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT01916057?

Interventions in NCT01916057: 18F-FDG PET Scan.

What condition does NCT01916057 study?

NCT01916057 studies Invasive Fungal Disease, Chronic Disseminated Candidiasis, Hematological Malignancies, Hematopoietic Stem Cell Transplantation, Neutropenia.

Is NCT01916057 still recruiting?

NCT01916057 is currently completed. Last updated 8 September 2025.

Last reviewed 2025-09-08 · How we verify

NCT01916057: CANHPARI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis

Completed NA Last updated 8 September 2025

What this trial tests

NA trial testing 18F-FDG PET Scan in Invasive Fungal Disease in 100 participants. Completed in 28 February 2018.

Timeline

19 November 2013

Primary endpoint
1 June 2017

28 February 2018

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	100
Start date	19 November 2013
Primary completion	1 June 2017
Estimated completion	28 February 2018
Sites	1 location across France

Drugs / interventions tested

18F-FDG PET Scan

Conditions studied

Invasive Fungal Disease — all drugs for Invasive Fungal Disease →
Chronic Disseminated Candidiasis — all drugs for Chronic Disseminated Candidiasis →
Hematological Malignancies — all drugs for Hematological Malignancies →
Hematopoietic Stem Cell Transplantation — all drugs for Hematopoietic Stem Cell Transplantation →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with Invasive Fungal Disease or Chronic Disseminated Candidiasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Understanding Pathogenesis and Care Challenges of Immune Reconstitution Inflammatory Syndrome in Fungal Infections.
Dellière S, Guery R, Candon S, Rammaert B, et al · · 2018 · cited 43× · PMID 30562960 · DOI 10.3390/jof4040139
9th Trends in Medical Mycology Held on 11-14 October 2019, Nice, France, Organized under the Auspices of EORTC-IDG and ECMM.
Gangneux JP, Lortholary O, Cornely OA, Pagano L. · · 2019 · cited 10× · PMID 31597285 · DOI 10.3390/jof5040095
Does <sup>18</sup>F-FDG PET/CT add value to conventional imaging in clinical assessment of chronic disseminated candidiasis?
Rammaert B, Maunoury C, Rabeony T, Correas JM, et al · · 2022 · cited 6× · PMID 36606049 · DOI 10.3389/fmed.2022.1026067
Fatal pulmonary hemorrhage, pneumothorax and skin necrosis caused by IRIS to an Aspergillus flavus infection in a young patient with metamizole associated agranulocytosis.
Banz M, Stallmach A, Gaßler N, Schulze PC, et al · · 2024 · cited 2× · PMID 38133714 · DOI 10.1007/s15010-023-02149-x
A Functional Polymorphism in IL-1B Is Associated With Immune Reconstitution Inflammatory Syndrome of Chronic Disseminated Candidiasis.
Rammaert B, Bochud PY, Brunel AS, Wojtowicz A, et al · · 2023 · cited 2× · PMID 36879623 · DOI 10.1093/ofid/ofad078

Verify or expand the search:

Other recruiting trials for Invasive Fungal Disease

Currently open trials in the same condition.

NCT07135778 — Liposomal Amphotericin B and Isavuconazole/Posaconazole in Br-IFD（ Breakthrough Invasive Fungal Disease） in Patients Wit · recruiting
NCT06819410 — Efficacy and Safety of Amphotericin B and Azoles in the Treatment of Invasive Fungal Disease · recruiting

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01916057 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 8 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01916057.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing